Introduction {#Sec1}
============

Camelids produce antibodies that are naturally devoid of light chains (Hamers-Casterman et al. [@CR5]). The single N-terminal domains of these heavy-chain antibodies (VHHs) are fully capable of antigen binding. They have several advantages for biotechnological purposes, such as a high physicochemical stability, a high production level in microorganisms, and the facile construction of genetic fusions of two VHH domains (Harmsen and De Haard [@CR11]). As a result, there is currently much interest in various therapeutic applications of VHHs (Harmsen and De Haard [@CR11]; Saerens et al. [@CR20]).

The mechanism of action of therapeutic antibody fragments is often based on blocking the interaction of their cognate antigen with a specific receptor. This is exemplified by antibodies neutralizing heat-labile toxin (LT), which is secreted by enterotoxigenic *E. coli*, and the closely related cholera toxin (CT), produced by *Vibrio cholerae*. Both toxins (reviewed by Spangler [@CR24]) cause diarrheal diseases and belong to the AB5 toxin family. The five B-subunits are responsible for holotoxin binding to the monosialoganglioside (GM1) receptor on intestinal epithelial cells (Cuatrecasas [@CR2]) after which the single A subunit is injected into the cells (Holmgren [@CR13]). Neutralizing antibodies generally bind to the B-subunit and block receptor interaction (Apter et al. [@CR1]). Similarly, virus neutralization by antibodies predominantly relies on the ability to block the interaction between the virion and a specific cellular receptor (Parren and Burton [@CR19]). Such blocking may occur due to direct binding to a viral epitope involved with receptor interaction. Consistent with this we observed that most potent foot-and-mouth disease virus (FMDV) neutralizing VHHs recognized an epitope called the GH-loop (Harmsen et al. [@CR12]), which binds to the cellular receptor. Alternatively, binding of a bulky antibody close to a site involved with receptor interaction may also prevent receptor interaction, a process called steric hindrance (Mateu and Verdaguer [@CR16]).

Due to their small size, VHHs are probably less well suited for steric hindrance. Increasing the size of VHHs by *N*-glycosylation could increase their neutralizing capacity. *N*-glycosylation occurs at Asn-X-Ser/Thr sequons, where X represents any amino acid except Pro. About 90% of such sites become *N*-glycosylated (Gavel and von Heijne [@CR4]). About 10% of the VHHs have such potential *N*-glycosylation sites (Harmsen et al. [@CR7]). *N*-glycosylation is a complex sequential process involving the transfer of a core-oligosaccharide to the protein within the endoplasmic reticulum and the addition of an outer-chain oligosaccharide within the Golgi apparatus. In mammals, the type of outer-chain glycosylation is highly variable between different proteins and sites and can be classified into high-mannose, hybrid, and complex-type glycosylation. Baker's yeast (*S. cerevisiae*) only adds outer chains consisting of α1--3- and α1--6-linked mannose residues. Depending on the particular glycosylation site, such yeast outer-chain glycosylation can result either in relatively short chains of about 10 kDa (core-like *N*-glycosylation) or very long chains with different lengths (high-mannose-type *N*-glycosylation) that have a molecular mass of 50--100 kDa (Kukuruzinska and Lennon [@CR14]). As a result, yeast *N*-glycosylation of small proteins such as VHHs that have an average size of 15 kDa, can result in a large increase in molecular mass.

We therefore analyzed the contribution of *N*-glycosylation of VHHs to their neutralizing capacity. We isolated several LT-binding VHHs and produced them by secretory yeast expression. A potent LT-neutralizing VHH was found to be *N*-glycosylated. We have further shown that its glycosylation contributes to its neutralization. We also showed that we could increase the FMDV-neutralizing capacity of two non-glycosylated VHHs by genetic fusion to another VHH that is glycosylated. The possible mechanism by which *N*-glycosylation improves neutralization capacity of VHHs is discussed.

Materials and methods {#Sec2}
=====================

Strains and genetic constructs {#Sec3}
------------------------------

*E. coli* XL1-Blue (Stratagene, La Jolla, CA) was used for routine recombinant DNA manipulation. *E. coli* TG1 (Stratagene) was used for phage display purposes. *S. cerevisiae* SU51 (YT6-2-1L) MATa; *can1*; *his4-519*; *leu2-3*, *−112*; *cir* ^*+*^, which is a cir^+^ derivative of AH22 (ATCC 38626), was used for VHH production as described previously (Van der Vaart [@CR28]).

Phage display selection of LT-binding VHHs {#Sec4}
------------------------------------------

The basic procedure for selection of antigen specific VHHs from immunized llamas by phage display using vector pUR4676 has been described before (Frenken et al. [@CR3]; Harmsen et al. [@CR8]). We immunized a single llama with 100 µg LT (Sigma, Saint Louis, MO) per immunization. Phage display selections of clones producing LT-binding VHHs were performed by biopanning (McCafferty and Johnson [@CR17]), using polystyrene 96-well plates coated with 0.1 or 0.01 µg/ml LT (Sigma). The VHH encoding regions of clones binding LT in ELISA were subjected to automated DNA sequencing as described previously (Harmsen et al. [@CR7]). The deduced VHH amino acid sequences were aligned according to the IMGT system (Lefranc [@CR15]) for alignment, numbering, and complementarity-determining region (CDR) definition of immunoglobulins. Additional gaps had to be introduced at the end of CDR2 to accommodate VHHs with unusually long CDR2s.

Yeast production of VHHs {#Sec5}
------------------------

LT-binding VHHs containing a C-terminal hexahistidine tag were produced by secretory yeast expression using plasmid pUR4584 and yeast strain SU51 (Harmsen et al. [@CR10]). For this purpose, VHH clones were transferred from pUR4676 to pUR4584 using the *Pst*I and *Bst*EII restriction sites. Single FMDV-binding VHHs M180 and M200 and the porcine immunoglobulin G binding VHH VI-12 were produced as described previously using vector pUR4585 (Harmsen et al. [@CR12]) with C-terminal c-myc and hexahistidine tags. The VHH2s M180shVI-12 and M200shVI-12 were produced as described previously (Harmsen et al. [@CR9]), but using the llama short-hinge sequence without cysteines (amino acid sequence AHHSEDPSSKSP) instead of the synthetic Gly--Gly--Ser linker for fusion of the two VHH domains. Secreted VHHs or VHH2s were purified by immobilized-metal affinity chromatography as described previously (Harmsen et al. [@CR10]). VHHs were deglycosylated by 16 h incubation of 5 mg/ml VHH with 2 U/ml endoglycosidase H (Roche Applied Science, Mannheim, Germany) at 37 °C in 50 mM sodium citrate, pH 5.5.

Vero cell assay {#Sec6}
---------------

The cytopathogenic effect (CPE) of LT on African green monkey kidney (Vero) cells was used to measure LT toxicity (Speirs et al. [@CR25]). Monolayers of Vero cells were grown in Minimal Essential Medium Eagles with Earle's salts and [l]{.smallcaps}-glutamine (EMEM; Invitrogen, San Diego, CA) and containing 10% normal calf serum in 96-well plates at 37 °C in a 5% CO~2~ atmosphere. The ability of VHHs to neutralize LT toxicity was determined by preincubating 100 µl 1 µg/L LT in Medium 199 without serum (Invitrogen) with a twofold dilution series of 10 mg/L VHH for 1 h at 37 °C. These mixtures were then transferred to the Vero cell monolayers. After a further 24-h incubation at 37 °C in a 5% CO~2~ atmosphere, the percentage of cells showing a CPE was microscopically determined. The VHH concentration required to inhibit the CPE on 75% of the cells was then determined.

ELISAs {#Sec7}
------

GM1, LT, CT, and the CT subunits A (CTA) and B (CTB) were all obtained from Sigma. For all ELISAs, high-binding polystyrene 96-well plates (Greiner, Solingen, Germany) were coated overnight at 4 °C with proteins in 50 mM carbonate/bicarbonate buffer, pH 9.6. LT was biotinylated using aminohexanoyl-biotin-*N*-hydroxysuccinimide (Zymed, San Francisco, CA) at a protein to biotin ratio of 100 on a weight basis.

The ability of VHHs to bind LT or CT holotoxins or their subunits was determined by incubation of plates coated with 1 mg/L of these antigens with twofold dilution series of 10 mg/L VHH in ELISA-buffer (1% skimmed milk; 0.05% Tween-20; 0.5 M NaCl; 2.7 mM KCl; 2.8 mM KH~2~PO~4~; 8.1 mM Na~2~HPO~4~; pH 7.4). Bound VHH was detected with peroxidase-conjugated polyclonal rabbit immunoglobulins anti-llama-immunoglobulin (Frenken et al. [@CR3]) and staining with 3,3′,5,5′ tetramethylbenzidine (TMB). The VHH concentration resulting in an extinction at 450 nm of 0.3 was then determined by nonlinear regression analysis.

The ability of anti-LT VHHs to inhibit binding of LT to GM1 was determined using an inhibition ELISA. Serial twofold dilution series of 10 mg/L VHH were preincubated with 0.1 mg/L biotinylated LT in 100 μl PBS containing 1% ovalbumin (Sigma; grade V) and 0.05% Tween-20 for 1 h at room temperature. These mixtures were then transferred to a plate coated with 0.2 mg/L GM1 and incubated for another hour. Bound biotinylated LT was then detected using peroxidase-conjugated streptavidin (Jackson Immunoresearch, West Grove, PA) and staining with TMB. The 50% inhibitory concentration (IC~50~) was calculated by interpolating the VHH concentration resulting in 50% of the extinction value obtained by a control incubation without VHH.

SDS-PAGE {#Sec8}
--------

VHHs (1 μg) were subjected to reducing SDS-PAGE, using precast gels (Novex, San Diego, CA), and stained using Sypro Orange and a STORM fosfor imager (Molecular Dynamics, Sunnyvale, CA).

*In vitro* FMDV neutralization assay {#Sec9}
------------------------------------

VHH concentrations required for neutralization of FMDV O~1~ Manisa were determined as described previously (Harmsen et al. [@CR12]) using 20 tissue culture infective doses required to infect 50% of the wells (TCID~50~) in duplicate assays using monolayers of secondary swine kidney cells and serial twofold dilutions of 10 mg/ml VHHs. When using endoglycosidase-H-treated VHH(2)s, we used a starting concentration of 1 mg/ml VHH(2).

Nucleotide sequence accession numbers {#Sec10}
-------------------------------------

Nucleotide sequences of selected anti-LT VHHs were submitted to the EMBL database under accession numbers AJ849409--AJ849413, AJ849415--AJ849427, AJ849431--AJ849438 and AJ849442 (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Multiple amino acid sequence alignment of *E. coli* LT-binding VHHs. *Dashes* indicate gaps introduced for sequence alignment. *Dots* indicate amino acids identical to the consensus sequence. Residue numbering and CDR definitions are according to the IMGT numbering system (Lefranc 2004). Residues 1--5 (amino acid sequence QVQLQ) and 143--145 (amino acid sequence VSS) are not shown since they are vector-encoded. The VHH clones are ranked according to CDR3-group and clone number. VHHs of the same CDR3 group are *boxed*. Potential *N*- glycosylation sites are indicated in *boldface*

Results {#Sec11}
=======

Isolation of LT-binding VHHs {#Sec12}
----------------------------

We isolated 180 clones producing VHHs that bound LT in ELISA by phage display selection from an immunized llama. After fingerprinting and sequence analysis, we obtained 27 unique VHHs (Fig. [1](#Fig1){ref-type="fig"}). Antibody variable domains, including VHHs, contain three complementarity-determining regions (CDRs) that are often directly involved in antigen binding (Muyldermans et al. [@CR18]). CDR3 generally is most variable (Harmsen et al. [@CR7]). Many of the 27 clones had similar CDR3 sequences, allowing the dissection into 11 CDR3 groups (A-K, Fig. [1](#Fig1){ref-type="fig"}).

Antigenic specificity of LT-binding VHHs {#Sec13}
----------------------------------------

The 27 unique VHHs were expressed in yeast and purified. The VHH concentration required to inhibit 75% (IC~75~) of the toxic effect of LT in a Vero cell assay ranges from more than 10 mg/L for non-neutralizing clones to 0.0017 for clone LT109 (Table [1](#Tab1){ref-type="table"}). Most neutralizing clones also inhibited binding of LT to its cellular receptor GM1, as determined by ELISA. Clone LT109 again had the lowest IC~50~ (Table [1](#Tab1){ref-type="table"}). The subunit specificity of LT-binding VHHs was determined using the commercially available subunits of the related CT. Most clones cross-reacted sufficiently to CT holotoxin to enable such determination (Table [1](#Tab1){ref-type="table"}). These VHHs required a similar VHH concentration for binding to the CT B-subunit and holotoxin, suggesting that they bind the B-subunit. The subunit specificity of LT104 and LT139 could not be determined due to insufficient cross reaction with CT (Table [1](#Tab1){ref-type="table"}). Table 1Toxin neutralization and antigenic specificity of LT-binding VHHsCloneVero cell assay IC~75~GM1-LT ELISA IC~50~Titer in ELISA (mg/L)Mean ± SD^a^ (mg/L)Mean ± SD (mg/L)LTCTCTBCTALT105\>10^b^±0\>10±00.0731.30.26\>10LT1063.3±00.028±0.0030.0320.250.12\>10LT1090.0017±0.00120.021±0.0080.180.120.15\>10LT109 endoH^c^0.0084±0.0050.06±0.024ND^d^NDNDNDLT128\>10±0\>10±00.0020.0980.027\>10LT1316.7±4.7\>10±00.0230.0230.012\>10LT132\>10±0\>10±00.0200.0240.013\>10LT1413.3±0\>10±00.0380.0190.016\>10LT143\>10±0\>10±00.0280.0400.016\>10LT101\>10±00.91±0.340.0424.61.6\>10LT104\>10±07.2±4.90.010\>108.6\>10LT1111.1±00.67±0.260.0423.10.83\>10LT116\>10±01.5±1.40.0100.660.21\>10LT133\>10±08.5±6.40.0594.11.6\>10LT1290.21±0.230.81±0.140.203.62.9\>10LT139\>10±00.18±0.110.0598.1\>10\>10LT1030.74±0.520.86±0.290.160.130.071\>10LT1240.12±00.27±0.110.0540.0370.033\>10LT1300.21±0.230.78±0.010.0350.0320.023\>10LT1540.39±0.030.96±1.020.0480.0220.016\>10LT1550.02±0.0090.21±0.250.0280.0140.010\>10LT1560.17±0.062.1±2.50.0240.0190.010\>10LT1610.27±0.212.9±3.60.200.0610.026\>10LT1630.07±0.050.18±0.030.0380.0260.024\>10LT1650.03±0.010.09±0.020.120.0420.043\>10LT1761.1±0.001.2±0.390.0400.0300.023\>10LT1681.4±0.390.03±0.000.0570.0420.038\>10LT1700.39±0.030.03±0.010.0730.0480.038\>10^a^SD, standard deviation^b^\>10, the VHH showed no effect at the highest concentration analyzed (10 mg/L)^c^endoH, sample that was deglycosylated by endoglycosidase H treatment^d^ND, not determined

Effect of VHH *N*-glycosylation on LT neutralization {#Sec14}
----------------------------------------------------

The VHHs LT109 and LT156 have potential *N*-glycosylation sites at IMGT positions 61 and 62, respectively, which are both located in CDR2 (Fig. [1](#Fig1){ref-type="fig"}). SDS-PAGE analysis showed that LT109 indeed consisted of a heterogeneous high-molecular-weight species, indicative of high-mannose type *N*-glycosylation, in addition to a minor amount of a discrete species of approximately 15 kDa which is expected for unglycosylated VHH (Fig. [2](#Fig2){ref-type="fig"}a). Deglycosylation of LT109 by endoglycosidase H treatment resulted in only this 15-kDa species, confirming that LT109 is partially glycosylated (Fig. [2](#Fig2){ref-type="fig"}q). Densitometric comparison of bands representing glycosylated and deglycosylated LT109 revealed that about 98 % of LT109 is glycosylated. A similar analysis revealed that LT156 is not glycosylated (Fig. [2](#Fig2){ref-type="fig"}a). Fig. 2Analysis of glycosylation of VHHs **a** and VHH2s **b** by SDS-PAGE. Samples were either treated (*+*) or mock-treated (*−*) with endoglycosidase H (*endoH*). The molecular mass of the markers used is indicated

Deglycosylation of LT109 resulted in a fivefold-increased IC~75~ in a Vero cell assay and a threefold-increased IC~50~ in a GM1-LT inhibition ELISA (Table [1](#Tab1){ref-type="table"}), indicating that *N*-glycosylation of LT109 contributes to its LT-neutralizing capacity.

Enhancement of virus neutralization by glycosylation of VHHs {#Sec15}
------------------------------------------------------------

We next analyzed the effect of VHH glycosylation on virus neutralization. For this purpose, we used two previously isolated FMDV-binding VHHs, M180, and M200, that lack potential *N*-glycosylation sites and neutralize FMDV in vitro (Harmsen et al. [@CR12]). These VHHs were genetically fused to a porcine IgG binding VHH, VI-12, that contains a high-mannose-type *N*-glycan at position 28 (Harmsen et al. [@CR9]). Both yeast-produced genetic fusions (VHH2s) were also efficiently glycosylated as revealed by analysis of endoglycosidase H-treated and untreated samples (Fig. [2](#Fig2){ref-type="fig"}b). These glycosylated VHH2s neutralized FMDV at at least fourfold-lower concentrations than observed with the corresponding individual FMDV-binding VHHs and at at least 50-fold-lower concentrations than their deglycosylated counterparts (Table [2](#Tab2){ref-type="table"}). This shows that VHH glycosylation contributes to FMDV neutralization. Table 2Effect of VHH2 glycosylation on FMDV neutralizationVHH(2)Endoglycosidase H treatmentFMDV neutralization (mg/ml)M180shVI-12−0.008M180shVI-12+1M200shVI-12−0.016M200shVI-12+1M180−0.22M200−0.059VI-12−\>10^a^VI-12+\>1*+* endoglycosidase H treatment, *−* mock incubation^a^No neutralization at the highest VHH concentration used

Discussion {#Sec16}
==========

After isolating 27 VHHs binding to *E. coli* LT, a single yeast-expressed clone, LT109, was found to be *N*-glycosylated at a single site. This clone was also found to neutralize LT most efficiently, suggesting that its *N*-glycosylation contributes to toxin neutralization. This is confirmed by the at least threefold-decreased neutralization efficiency of enzymatically deglycosylated LT109. About 98 % of the LT109 molecules are glycosylated. Such partial glycosylation of sites is more often observed (Kukuruzinska and Lennon [@CR14]). The presence of some unglycosylated LT109 complicates determination of the exact contribution of *N*-glycosylation to toxin neutralization since the glycosylated VHH could bind to LT with lower affinity. This is not unlikely since the glycosylation site of LT109 is located within CDR2, a region which is often directly involved in antigen binding (Muyldermans et al. [@CR18]).

Most VHHs bound the B-subunit and their ability to neutralize LT in vitro seemed to correlate with their ability to inhibit toxin binding to the GM1 receptor, as measured by an inhibition ELISA. This is consistent with previous findings in the many studies on conventional monoclonal antibodies against LT or CT, and the view that toxin neutralization relies on inhibition of toxin receptor interaction (Spangler [@CR24]; Apter et al. [@CR1]). Since LT contains five GM1 binding sites (Sixma et al. [@CR23]), neutralizing VHHs must inhibit multiple receptor interactions. This can be accomplished either by binding of multiple VHHs to a single LT molecule or by blocking of multiple receptor sites by a single VHH. In the latter case, an increased size of the VHH due to *N*-glycosylation is likely to increase toxin neutralization. Possibly, the glycosylation occurring close to the antigen-binding site results in more efficient blocking of toxin receptor sites as compared to glycosylation occurring more distant from the antigen-binding site. It remains to be determined whether glycosylation of VHHs also increases inhibition of monovalent interactions.

We also assessed the effect of VHH glycosylation on virus neutralization using two VHHs that are able to bind FMDV. These VHHs naturally lacked potential glycosylation sites. They were indirectly glycosylated by genetic fusion to another VHH that was known to be glycosylated. This successful approach could generally be applied to obtain glycosylation of VHHs. In both cases, the *N*-glycosylation improved the FMDV neutralizing capacity at least fourfold. One of these VHHs, clone M200, binds to the GH-loop (Harmsen et al. [@CR12]), which directly binds to the cellular receptor. As a result, it is unlikely that the increased neutralization relies on interference of the oligosaccharide with the GH-loop to which the VHH binds. However, each virion contains 60 GH-loop copies (Mateu and Verdaguer [@CR16]). Possibly, the increased neutralization of the GH-loop-binding clone M200 due to *N*-glycosylation results from steric hindrance of other GH-loop-receptor interactions on the virion surface.

Protein glycosylation can also contribute to protein stability after in vivo application (Sinclair and Elliott [@CR22]). Since we studied the effect of neutralization in vitro and because non-glycosylated VHHs already have a high physicochemical stability (Van der Linden et al. [@CR27]), it is unlikely that the decreased toxin or virus neutralization by deglycosylated VHHs results from reduced stability.

Parenteral application to mammals of proteins containing terminally mannosylated carbohydrates, such as those occurring in yeast, results in their rapid clearance in vivo due to binding to high-mannose receptors in the liver (Wright and Morrison [@CR29]). This complicates the immunotherapeutic use of *N*-glycosylated FMDV-binding VHHs, which should be applied parenterally, but not of LT-binding VHHs, which should be delivered to the intestinal lumen by oral application. The use of recombinant yeast strains (Hamilton and Gerngross [@CR6]) or plants (Strasser et al. [@CR26]) that are engineered to produce proteins with human-like glycosylation for production of glycosylated VHHs could prevent rapid in vivo clearance after parenteral application.

Normally non-glycosylated VHHs can be converted to *N*-glycosylated VHHs by the introduction of potential *N*-glycosylation sites by site-directed mutagenesis (Sagt et al. [@CR21]). Thus, the neutralization capacity of VHHs could possibly be further increased by obtaining glycosylation on single or even multiple sites that are located distant from the VHH antigen-binding site. Such an approach has the additional benefit of an increased yeast production level of glycosylated VHHs (Sagt et al. [@CR21]).
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